GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series



Summary

This case series highlights a newly recognized side effect of talquetamab, a GPRC5D-targeting bispecific antibody used to treat multiple myeloma: a distinct dizziness-ataxia syndrome. The study details the clinical presentation, characterized by balance impairment and neurological symptoms, observed in patients treated with talquetamab. It emphasizes the importance of early recognition of this syndrome to differentiate it from other neurological toxicities. The authors also provide insights into effective management strategies, including dose adjustments and supportive care, aimed at mitigating the symptoms and allowing patients to continue benefitting from talquetamab treatment.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!